文献速递眼整形与眼眶神经眼科

替妥木单抗治疗甲状腺眼病后的听力功能障碍

Hearing Dysfunction After Treatment With Teprotumumab for Thyroid Eye Disease.
PubMed 文献 · Am J Ophthalmol · 2022-02-25

这项前瞻性观察性病例系列纳入27例接受至少4次替妥木单抗输注的甲状腺眼病患者,22例(81.5%)出现新的主观耳科症状,多数耳鸣、耳闷胀感和自听过强可缓解,但主观听力下降/词语理解力下降仅45.5%缓解,5例听力学检查发现替妥木单抗相关感音神经性听力损失,既往听力损失史为危险因素(P = .008)。

要点

  • 27例中22例(81.5%)出现新发主观耳科症状,平均在3.8次输注后出现(SD 1.8)。
  • 耳鸣、耳闷胀感/堵塞感和自听过强多数缓解,主观听力下降/词语理解力下降仅45.5%(5/11)缓解。
  • 5例听力学检查发现替妥木单抗相关感音神经性听力损失,其中3例末次随访仍有主观听力下降。

核心结论

  • 听力损失是替妥木单抗值得关注的不良事件,其机制和可逆性应进一步研究。
  • 在听力损失危险因素被更好理解之前,作者建议基线听力学检查加咽鼓管异常开放(PET)测试,并出现新发耳科症状时重复检查。
  • 需要筛查、监测和预防指南。

研究设计与样本

  • 前瞻性观察性病例系列。
  • 连续纳入接受至少4次替妥木单抗输注的甲状腺眼病患者,共分析27例(24例女性,3例男性,平均56.3岁)。
  • 在基线、第2、4、8次输注后及6个月随访时进行眼科检查与不良事件评估(包括耳科症状),基线和治疗期间收集实验室检查结果。
  • 对新发或加重的耳科症状患者进行听力学检查、咽鼓管异常开放测试和耳鼻喉科评估,其中一部分患者获得基线和治疗后测试。

主要发现

  • 22例(81.5%)出现新发主观耳科症状,平均在3.8次输注后出现(SD 1.8)。
  • 末次输注后平均39.2周随访时,耳鸣患者100%、耳闷胀感/堵塞感患者90.9%、自听过强患者83.3%症状缓解,而主观听力下降/词语理解力下降患者仅45.5%(5/11)缓解。
  • 6例接受基线和治疗后听力学检查,其中5例出现替妥木单抗相关感音神经性听力损失(SNHL),1例同时出现咽鼓管异常开放。
  • 5例替妥木单抗相关感音神经性听力损失患者中3例在末次随访时仍有主观听力下降。
  • 既往听力损失史被发现有替妥木单抗相关感音神经性听力损失的危险因素(P = .008)。

临床怎么用

  • 作者建议基线进行听力学检查加咽鼓管异常开放测试,并在出现新发耳科症状时重复测试。
  • 作者指出需要筛查、监测和预防指南。

局限性

  • 原文结论指出听力损失的机制和可逆性应进一步研究。
  • 原文结论指出在听力损失危险因素被更好理解之前,作者建议基线听力学检查加咽鼓管异常开放测试并出现新发耳科症状时重复检查。
  • 原文结论指出需要筛查、监测和预防指南。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To characterize the frequency, severity, and resolution of hearing dysfunction in patients treated with teprotumumab for thyroid eye disease (TED). DESIGN: Prospective observational case series. METHODS: Ophthalmic examination and adverse event assessment, including otologic symptoms, were performed at baseline, after infusions 2, 4, and 8, and at 6-month follow-up in consecutive patients who received at least 4 teprotumumab infusions. Laboratory test results were collected at baseline and during treatment. Audiometry, patulous eustachian tube (PET) testing, and otolaryngology evaluation were obtained for patients with new or worsening otologic symptoms, with a subset obtaining baseline and posttreatment testing. RESULTS: Twenty-seven patients were analyzed (24 females, 3 males, average 56.3 years old). Twenty-two patients (81.5%) developed new subjective otologic symptoms, after a mean of 3.8 infusions (SD 1.8). At 39.2-week average follow-up after the last infusion, most patients with tinnitus (100%), ear plugging/fullness (90.9%), and autophony (83.3%) experienced symptom resolution, whereas only 45.5% (5 of 11) of patients with subjective hearing loss/decreased word comprehension experienced resolution. Six patients underwent baseline and posttreatment audiometry, 5 of whom developed teprotumumab-related sensorineural hearing loss (SNHL) and 1 patient also developed PET. Three of the 5 patients with teprotumumab-related SNHL had persistent subjective hearing loss at last follow-up. A prior history of hearing loss was discovered as a risk factor for teprotumumab-related SNHL (P = .008). CONCLUSIONS: Hearing loss is a concerning adverse event of teprotumumab, and its mechanism and reversibility should be further studied. Until risk factors for hearing loss are better understood, we recommend baseline audiometry with PET testing and repeat testing if new otologic symptoms develop. Screening, monitoring, and prevention guidelines are needed.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Sears CM, Azad AD, Amarikwa L, et al. Hearing Dysfunction After Treatment With Teprotumumab for Thyroid Eye Disease. Am J Ophthalmol. 2022. PMID: 35227694. doi:10.1016/j.ajo.2022.02.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。